An FDA approval is setting a new benchmark for future treatment for first-line small cell lung cancer. The FDA has greenlighted Jazz Pharmaceuticals’ Zepzelca, used in combination with Roche’s ...
T cell engagers, including Imdelltra, show promise in small cell lung cancer, outperforming chemotherapy in trials and changing the standard of care. Antibody-drug conjugates like I-DXd and ABBV-706 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback